109 related articles for article (PubMed ID: 9533776)
1. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
Lydon NB; Mett H; Mueller M; Becker M; Cozens RM; Stover D; Daniels D; Traxler P; Buchdunger E
Int J Cancer; 1998 Mar; 76(1):154-63. PubMed ID: 9533776
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
4. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
6. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
9. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
Cassinelli G; Lanzi C; Pensa T; Gambetta RA; Nasini G; Cuccuru G; Cassinis M; Pratesi G; Polizzi D; Tortoreto M; Zunino F
Biochem Pharmacol; 2000 Jun; 59(12):1539-47. PubMed ID: 10799650
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.
Buchdunger E; Trinks U; Mett H; Regenass U; Müller M; Meyer T; McGlynn E; Pinna LA; Traxler P; Lydon NB
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2334-8. PubMed ID: 8134396
[TBL] [Abstract][Full Text] [Related]
11. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
Yaish P; Gazit A; Gilon C; Levitzki A
Science; 1988 Nov; 242(4880):933-5. PubMed ID: 3263702
[TBL] [Abstract][Full Text] [Related]
12. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
Gazit A; Yaish P; Gilon C; Levitzki A
J Med Chem; 1989 Oct; 32(10):2344-52. PubMed ID: 2552117
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin.
Korutla L; Cheung JY; Mendelsohn J; Kumar R
Carcinogenesis; 1995 Aug; 16(8):1741-5. PubMed ID: 7634398
[TBL] [Abstract][Full Text] [Related]
14. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
16. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.
Fry DW; Nelson JM; Slintak V; Keller PR; Rewcastle GW; Denny WA; Zhou H; Bridges AJ
Biochem Pharmacol; 1997 Oct; 54(8):877-87. PubMed ID: 9354588
[TBL] [Abstract][Full Text] [Related]
18. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
19. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation.
McIntyre BS; Sylvester PW
Cell Prolif; 1998 Feb; 31(1):35-46. PubMed ID: 9666817
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]